Core Viewpoint - 康龙化成 has signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong to issue 58,440,762 new H-shares at a price of HKD 22.82 per share, aiming to raise approximately HKD 1,333.6 million [1][2] Group 1 - The placement shares represent approximately 19.86% of the existing issued H-shares and 3.30% of the total issued shares as of the announcement date [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1,318.7 million, with a net price per share of approximately HKD 22.56 [2] - The company plans to allocate about 70% of the net proceeds for project construction to enhance laboratory service facilities and production capacity [2] Group 2 - Approximately 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the company's capital structure [2] - About 20% of the funds will be allocated to supplement working capital and other general corporate purposes [2] - The board believes that this issuance will strengthen the company's financial position, capture industry opportunities, and support capacity investment and business expansion [2]

Core Viewpoint - 康龙化成 plans to raise approximately HKD 13.3 billion through the placement of new H-shares, with a focus on enhancing its laboratory and production capabilities, optimizing its capital structure, and supplementing working capital [1] Group 1: Financing Details - 康龙化成 announced the issuance of 58,440,762 new H-shares at a price of HKD 22.82, representing an 8.5% discount to the previous closing price of HKD 24.94 and a 1.6% discount to the average closing price of HKD 23.20 over the past five trading days [1] - The new shares represent approximately 3.3% of the existing issued share capital and will account for about 3.2% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 9.3 billion of the proceeds will be allocated for project construction to enhance laboratory and production capacity [1] - Around HKD 1.3 billion will be used to repay loans to optimize the capital structure [1] - Approximately HKD 2.6 billion will be designated for working capital and general corporate purposes [1] Group 3: Transaction Timeline - The issuance is based on a general authorization granted by the shareholders and is expected to be completed by January 22, 2026 [1]